Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,100
-60 (-0.59%)
Sep 11, 2026, 3:30 PM KST

KRX:271980 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
543,495567,244704,542726,394722,230700,693
Other Revenue
-0-0-0-0-0-0
543,495567,244704,542726,394722,230700,693
Revenue Growth
-17.85%-19.49%-3.01%0.58%3.07%1.35%
Cost of Revenue
323,467354,341527,047542,138565,432545,122
Gross Profit
220,028212,904177,495184,256156,798155,571
Selling, General & Admin
153,523145,422138,562131,225128,897125,363
Research & Development
59,14144,97138,77245,72741,14738,974
Other Operating Expenses
926.8832.5919,750511.83456.31-11.35
Operating Expenses
215,949191,908196,044175,368170,130165,951
Operating Income
4,07920,995-18,5508,888-13,332-10,380
Interest Expense
-4,651-4,395-5,057-6,033-3,009-1,967
Interest & Investment Income
1,7201,5651,1831,031115.675.84
Earnings From Equity Investments
-----2,516
Currency Exchange Gain (Loss)
4,49032.492,162-225.0599.9390.65
Other Non Operating Income (Expenses)
-48.48155.98-7,310-2,359946.33-3,311
EBT Excluding Unusual Items
5,59018,354-27,5711,302-15,180-12,975
Gain (Loss) on Sale of Investments
13,08816,5851,136614.011,923-506.61
Gain (Loss) on Sale of Assets
912.087.970.539.9930
Asset Writedown
---531.3---382
Pretax Income
18,68734,950-26,9591,916-13,247-13,834
Income Tax Expense
-3,2002,9493,184-3,2841,7621,152
Earnings From Continuing Operations
21,88632,001-30,1435,201-15,009-14,986
Minority Interest in Earnings
-12,570-8,617174.67-195.831,9182,512
Net Income
9,31723,384-29,9685,005-13,091-12,473
Net Income to Common
9,31723,384-29,9685,005-13,091-12,473
Net Income Growth
80.48%-----
Shares Outstanding (Basic)
151515151515
Shares Outstanding (Diluted)
151515151515
Shares Change
0.35%0.02%-0.02%-0.02%-0.23%-0.04%
EPS (Basic)
637.361604.77-2057.00343.46-898.19-853.81
EPS (Diluted)
637.361604.77-2057.00343.46-898.19-853.81
EPS Growth
79.85%-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-15,816-13,722-1,065-11,077-26,23213,756
Free Cash Flow Per Share
-1081.95-941.70-73.10-760.21-1799.81941.63
Dividend Per Share
---50.00050.000-
Dividend Growth
---0%--
Gross Margin
40.48%37.53%25.19%25.37%21.71%22.20%
Operating Margin
0.75%3.70%-2.63%1.22%-1.85%-1.48%
Profit Margin
1.71%4.12%-4.25%0.69%-1.81%-1.78%
Free Cash Flow Margin
-2.91%-2.42%-0.15%-1.52%-3.63%1.96%
EBITDA
16,94233,312-7,25318,655-4,446-1,247
EBITDA Margin
3.12%5.87%-1.03%2.57%-0.62%-0.18%
D&A For EBITDA
12,86312,31711,2979,7678,8869,133
EBIT
4,07920,995-18,5508,888-13,332-10,380
EBIT Margin
0.75%3.70%-2.63%1.22%-1.85%-1.48%
Effective Tax Rate
-8.44%----
Advertising Expenses
-9,6699,8849,30911,78614,512